TrialNature communications2024

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.

Mark C Markowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.